title: Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus.
abstract: OBJECTIVE
  To study bone mineral density (BMD) and bone remodeling factors at the time of diagnosis of adult-onset type 1 diabetes mellitus (DM).
  
  
  METHODS
  In 22 men and 10 women, who ranged in age from 20 to 39 years, a study was undertaken promptly after diagnosis of type 1 DM (on the basis of criteria established by the World Health Organization). Before any treatment, the clinical history, glycemia, ketonuria, basal and glucagon-stimulated C-peptide levels, islet cell antibodies (ICA), glutamic acid decarboxylase autoantibodies (GADA), and bone remodeling variables were recorded for all the study subjects. Dual-energy x-ray absorptiometry (Hologic QDR1000) was performed to measure BMD in the lumbar spine (LS), femoral neck (FN), and Ward's triangle.
  
  
  RESULTS
  Of the 32 patients, 24 (75%) showed positive levels of ICA or GADA (or both), whereas 8 (25%) tested negative. The BMD values-Z-scores (standard deviation [SD] adjusted for age and sex)-were lower among the patients with DM than in a matched healthy population in both the LS (-0.61 +/- 1.23 SD; P = 0.008) and the FN (-0.38 +/- 1.00 SD; P = 0.003). Twelve patients had a T-score between -2.5 SD and -1 SD in the LS, and 14 had the same scores in the FN and were classified as having osteopenia. A correlation was found between BMD values and C-peptide levels in the LS (r = 0.231; P = 0.02) and the FN (r = 0.27; P = 0.01). The BMD values did not correlate with bone remodeling markers, hemoglobin A1c, or immunologic variables.
  
  
  CONCLUSIONS
  We found reduced bone mass in patients with type 1 DM at the time of the clinical diagnosis. A high percentage of patients with DM have osteopenia, which may not, therefore, be a late complication of type 1 DM. These findings need to be confirmed in larger studies.
authors.affiliation: Endocrinology Service, Department of Medicine, San Cecilio University Hospital, C/Ancha de Gracia, 4 4(o) B, 18002 Granada, Spain.
authors.forename: P J
authors.initials: PJ
authors.lastname: López-Ibarra
authors.forename: M M
authors.initials: MM
authors.lastname: Pastor
authors.forename: F
authors.initials: F
authors.lastname: Escobar-Jiménez
authors.forename: M D
authors.initials: MD
authors.lastname: Pardo
authors.forename: A G
authors.initials: AG
authors.lastname: González
authors.forename: J D
authors.initials: JD
authors.lastname: Luna
authors.forename: M E
authors.initials: ME
authors.lastname: Requena
authors.forename: M A
authors.initials: MA
authors.lastname: Diosdado
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D001323:Autoantibodies / Q000097:blood; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000175:diagnosis; D016723:Bone Remodeling; D002096:C-Peptide / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology*; D005260:Female; D005272:Femur Neck; D005968:Glutamate Decarboxylase / Q000276:immunology; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology; D008159:Lumbar Vertebrae; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis
chemical_list: D001323:Autoantibodies; D002096:C-Peptide; D005968:Glutamate Decarboxylase; D006442:Glycated Hemoglobin